• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For May 12, 2023

    5/12/23 8:22:35 AM ET
    $AC
    $ACXP
    $ADAP
    $AGIL
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AC alert in real time by email

    Companies Reporting Before The Bell

    • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

    • Welltower (NYSE:WELL) is likely to report quarterly loss at $0.02 per share on revenue of $159.38 million.

    • Associated Cap Gr (NYSE:AC) is projected to report quarterly loss at $0.74 per share on revenue of $4.35 billion.

    • NeoGenomics (NASDAQ:NEO) is likely to report quarterly earnings at $0.16 per share on revenue of $201.13 million.

    • Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:CWEB) is projected to report quarterly loss at $0.07 per share on revenue of $25.35 million.

    • Crescent Point Energy (NYSE:CPG) is estimated to report quarterly earnings at $0.30 per share on revenue of $641.86 million.

    • AgileThought (NASDAQ:AGIL) is expected to report quarterly loss at $0.16 per share on revenue of $43.09 million.

    • China Automotive Systems (NASDAQ:CAAS) is likely to report quarterly earnings at $0.12 per share on revenue of $142.67 million.

    • Bio-Path Hldgs (NASDAQ:BPTH) is likely to report earnings for its first quarter.

    • Dingdong (Cayman) (NYSE:DDL) is estimated to report earnings for its first quarter.

    • The Real Good Food (NASDAQ:RGF) is projected to report quarterly loss at $0.24 per share on revenue of $26.12 million.

    • Longeveron (NASDAQ:LGVN) is estimated to report quarterly loss at $0.21 per share on revenue of $300 thousand.

    • Augmedix (NASDAQ:AUGX) is likely to report quarterly loss at $0.15 per share on revenue of $9.36 million.

    • Impel Pharmaceuticals (NASDAQ:IMPL) is projected to report quarterly loss at $0.90 per share on revenue of $5.73 million.

    • Soho House (NYSE:SHCO) is estimated to report quarterly loss at $0.17 per share on revenue of $260.01 million.

    • Acurx Pharmaceuticals (NASDAQ:ACXP) is projected to report earnings for its first quarter.

    • American Shared Hospital (AMEX:AMS) is estimated to report earnings for its first quarter.

    • Humacyte (NASDAQ:HUMA) is projected to report quarterly loss at $0.21 per share on revenue of $170 thousand.

    • AirSculpt Technologies (NASDAQ:AIRS) is likely to report quarterly loss at $0.02 per share on revenue of $42.96 million.

    • LifeMD (NASDAQ:LFMD) is estimated to report quarterly loss at $0.16 per share on revenue of $30.80 million.

    • Biofrontera (NASDAQ:BFRI) is likely to report quarterly loss at $0.19 per share on revenue of $9.15 million.

    • Embecta (NASDAQ:EMBC) is estimated to report quarterly earnings at $0.49 per share on revenue of $262.88 million.

    • American Strategic (NYSE:NYC) is expected to report earnings for its first quarter.

    • Delcath Systems (NASDAQ:DCTH) is projected to report quarterly loss at $0.61 per share on revenue of $770 thousand.

    • Adaptimmune Therapeutics (NASDAQ:ADAP) is estimated to report quarterly loss at $0.14 per share on revenue of $4.93 million.

    • Spectrum Brands Holdings (NYSE:SPB) is projected to report quarterly loss at $0.04 per share on revenue of $761.66 million.

    Companies Reporting After The Bell

    • Eastside Distilling (NASDAQ:EAST) is estimated to report quarterly loss at $0.12 per share on revenue of $4.51 million.

    • Oxbridge Re Holdings (NASDAQ:OXBR) is estimated to report earnings for its first quarter.

    • Simon Property Group (NYSE:SPG) is estimated to report quarterly loss at $0.01 per share on revenue of $69.80 million.

    • Bridger Aerospace Gr (NASDAQ:BAER) is likely to report earnings for its first quarter.

    • Forian (NASDAQ:FORA) is likely to report quarterly loss at $0.11 per share on revenue of $5.70 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AC
    $ACXP
    $ADAP
    $AGIL

    CompanyDatePrice TargetRatingAnalyst
    Simon Property Group Inc.
    $SPG
    1/20/2026$205.00Hold → Buy
    Deutsche Bank
    Welltower Inc.
    $WELL
    12/18/2025$205.00Overweight → Neutral
    Analyst
    Welltower Inc.
    $WELL
    11/5/2025$208.00In-line → Outperform
    Evercore ISI
    Welltower Inc.
    $WELL
    10/1/2025$195.00Overweight
    Cantor Fitzgerald
    Welltower Inc.
    $WELL
    9/19/2025$195.00Buy
    UBS
    Simon Property Group Inc.
    $SPG
    9/15/2025$187.00Outperform → In-line
    Evercore ISI
    Simon Property Group Inc.
    $SPG
    9/2/2025$179.00Buy → Hold
    Stifel
    Humacyte Inc.
    $HUMA
    8/27/2025$3.50Overweight
    Barclays
    More analyst ratings

    $AC
    $ACXP
    $ADAP
    $AGIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Schorsch Nicholas S bought $19,269 worth of shares (1,664 units at $11.58) (SEC Form 4)

    4 - American Strategic Investment Co. (0001595527) (Issuer)

    2/2/26 9:31:35 PM ET
    $NYC
    Real Estate Investment Trusts
    Real Estate

    Director Popstefanov Gjorgi bought $99,999,999 worth of shares (11,111,111 units at $9.00) (SEC Form 4)

    4 - Soho House & Co Inc. (0001846510) (Issuer)

    2/2/26 6:59:52 PM ET
    $SHCO
    Hotels/Resorts
    Consumer Discretionary

    Large owner Schorsch Nicholas S bought $55,594 worth of shares (4,992 units at $11.14) (SEC Form 4)

    4 - American Strategic Investment Co. (0001595527) (Issuer)

    1/29/26 9:11:35 PM ET
    $NYC
    Real Estate Investment Trusts
    Real Estate

    $AC
    $ACXP
    $ADAP
    $AGIL
    SEC Filings

    View All

    SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.

    424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/11/26 4:21:38 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.

    SCHEDULE 13G/A - Biofrontera Inc. (0001858685) (Subject)

    2/11/26 11:31:16 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Welltower Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - WELLTOWER INC. (0000766704) (Filer)

    2/10/26 4:05:53 PM ET
    $WELL
    Real Estate Investment Trusts
    Real Estate

    $AC
    $ACXP
    $ADAP
    $AGIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cicco Martin J was granted 299 shares (SEC Form 4)

    4 - SIMON PROPERTY GROUP INC. (0001063761) (Issuer)

    2/9/26 4:30:55 PM ET
    $SPG
    Real Estate Investment Trusts
    Real Estate

    SEC Form 3 filed by new insider Cicco Martin J

    3 - SIMON PROPERTY GROUP INC. (0001063761) (Issuer)

    2/9/26 4:27:37 PM ET
    $SPG
    Real Estate Investment Trusts
    Real Estate

    SEC Form 3 filed by new insider Rayman Reed B

    3 - Soho House & Co Inc. (0001846510) (Issuer)

    2/9/26 1:31:29 PM ET
    $SHCO
    Hotels/Resorts
    Consumer Discretionary

    $AC
    $ACXP
    $ADAP
    $AGIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    embecta names new Chairman of the Board and Lead Independent Director

    PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the "Board") of embecta has elected Devdatt "Dev" Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company. Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabete

    2/11/26 4:10:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

    Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted filing of the Company's supplemental Ne

    2/11/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Honda Motor Co., Ltd. (HMC:NYSE) announced its consolidated financial results for the fiscal third quarter ended December 31, 2025.

    TOKYO, Feb. 10, 2026 /PRNewswire/ -- Honda Motor Co., Ltd. today announced its consolidated financial results for the fiscal third quarter ended December 31, 2025. Q3 Ended December 31, 2025 Financial Results Operating Profit 591.5 bil. yenIn motorcycle business, sales remained solid, primarily due to India and Brazil.In automobile business, the impact of tariffs as well as one time expenses related to EVs resulted in a decrease in profits.Operating cash flows after R&D adjustment 1,855.8 bil. yenFYE March 31, 2026 Financial Forecast Operating Profit 550.0 bil. yen / Profit for the year 300.0 bil. yenDue to a wide range of efforts, incl. collaboration with suppliers, tariff impact was reduc

    2/10/26 11:03:00 PM ET
    $HMC
    Auto Manufacturing
    Industrials

    $AC
    $ACXP
    $ADAP
    $AGIL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $AC
    $ACXP
    $ADAP
    $AGIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Simon Properties upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Simon Properties from Hold to Buy and set a new price target of $205.00

    1/20/26 8:46:55 AM ET
    $SPG
    Real Estate Investment Trusts
    Real Estate

    Welltower downgraded by Analyst with a new price target

    Analyst downgraded Welltower from Overweight to Neutral and set a new price target of $205.00

    12/18/25 9:02:49 AM ET
    $WELL
    Real Estate Investment Trusts
    Real Estate

    Welltower upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Welltower from In-line to Outperform and set a new price target of $208.00

    11/5/25 7:25:28 AM ET
    $WELL
    Real Estate Investment Trusts
    Real Estate

    $AC
    $ACXP
    $ADAP
    $AGIL
    Leadership Updates

    Live Leadership Updates

    View All

    Pebblebrook Hotel Trust Elects Nina P. Jones and Bill Bayless to Board of Trustees

    The Company also announced the adoption of a New Principles-Based Board Refreshment Framework Pebblebrook Hotel Trust (NYSE:PEB) (the "Company" or "Pebblebrook") today announced the election of Nina P. Jones and Bill Bayless to the Board of Trustees. Ms. Jones's election is effective March 1, 2026. Mr. Bayless is expected to join the Board during the fourth quarter of 2026. Ms. Jones retired from T. Rowe Price, a global investment manager with over $1 trillion in assets under management, where she most recently served as Vice President, Portfolio Manager of the U.S. Real Estate Equity Strategy. She has more than 15 years of real estate investing experience at T. Rowe Price, also serving

    2/9/26 7:00:00 AM ET
    $EQR
    $PEB
    $SPG
    Real Estate Investment Trusts
    Real Estate

    Simon Property Group Announces Appointment of Martin J. Cicco to Board of Directors

    INDIANAPOLIS, Feb. 5, 2026  /PRNewswire/ -- Simon®, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, announced today that Martin J. Cicco has been appointed to the Board of Directors. Mr. Cicco has over 45 years of real estate and capital markets experience, including initiating Evercore Partners' Real Estate Strategic Advisory practice after founding MJC Associates. Prior to joining Evercore, Mr. Cicco spent 29 years at Merrill Lynch & Co., ultimately serving as Vice Chairman of Global Commercial Re

    2/5/26 4:05:00 PM ET
    $SPG
    Real Estate Investment Trusts
    Real Estate

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AC
    $ACXP
    $ADAP
    $AGIL
    Financials

    Live finance-specific insights

    View All

    Welltower Reports Fourth Quarter 2025 Results

    TOLEDO, Ohio, Feb. 10, 2026 /PRNewswire/ -- Welltower Inc. (NYSE:WELL) today announced results for the quarter ended December 31, 2025. Fourth Quarter and Other Recent Highlights Reported net income attributable to common stockholders of $0.14 per diluted shareReported quarterly normalized funds from operations attributable to common stockholders of $1.45 per diluted share, an increase of 28.3% over the prior yearReported total portfolio year-over-year same store NOI ("SSNOI") growth of 15.0%, driven by SSNOI growth in our Seniors Housing Operating ("SHO") portfolio of 20.4%SH

    2/10/26 4:05:00 PM ET
    $WELL
    Real Estate Investment Trusts
    Real Estate

    Dingdong Announces Intention to Utilize Substantial Majority of Proceeds from Sale of China Operations for Share Repurchase Plans and/or Dividends upon Closing of Transaction

    SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- Dingdong (Cayman) Limited ("Dingdong Cayman" or the "Company") (NYSE:DDL), a leading fresh grocery e-commerce company in China, today announced that it intends to utilize a substantial majority of the cash proceeds from the sale of its China operations upon the closing of such Transaction (as defined below) for share repurchases or the issuance of dividends to its shareholders. As previously disclosed on February 5, 2026, the Company entered into a definitive Share Purchase Agreement (the "Share Purchase Agreement") with Two Hearts Investments Limited ("Buyer"), a wholly-owned subsidiary of Meituan (HKEX: 3690). Pursuant to the Share Purchase Agreemen

    2/10/26 8:00:00 AM ET
    $DDL
    Catalog/Specialty Distribution
    Consumer Discretionary

    Spectrum Brands Holdings Reports Fiscal 2026 First Quarter Results

    First Quarter Net Sales Decreased 3.3% and Organic Net Sales Decreased 6.0% First Quarter Net Income From Continuing Operations of $29.4 Million and Adjusted EBITDA of $62.6 Million First Quarter Operating Cash Flow From Continuing Operations of $67.7 Million and Adjusted Free Cash Flow of $59.7 Million Repurchased 0.6 Million Shares in Q1 for $36 Million; New $300 Million Share Repurchase Authorization Approved Ended First Quarter with Net Debt Leverage of 1.65x Adjusted EBITDA Reiterating Fiscal 2026 Framework, Continue to Expect Net Sales to be Flat to Up Low Single Digits, Low Single Digit Growth in Adjusted EBITDA, and Approximately 50% Conversion of Adjusted EBITDA to

    2/5/26 6:30:00 AM ET
    $SPB
    Industrial Machinery/Components
    Miscellaneous

    $AC
    $ACXP
    $ADAP
    $AGIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by American Shared Hospital Services

    SC 13D - AMERICAN SHARED HOSPITAL SERVICES (0000744825) (Subject)

    11/20/24 4:59:03 PM ET
    $AMS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care